Summary & Overview
CPT 86850: Antibody Screen, Each Serum Technique
CPT 86850 represents an antibody screen performed by each serum technique to detect unexpected red cell antibodies prior to transfusion or during diagnostic evaluation. Nationally, antibody screening is a core transfusion-medicine laboratory service that supports patient safety, blood compatibility, and treatment planning for hemolytic conditions. The code applies to lab-based immunohematology workflows where identification of clinically significant alloantibodies informs transfusion decisions and therapeutic monitoring.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication provides a concise overview of coverage considerations across major commercial payers, common clinical contexts supporting use of the code, and its relationship to related serologic procedures.
Readers will learn: the clinical purpose of the procedure, typical site-of-service expectations, common ICD-10 diagnosis contexts that justify testing, related CPT codes used in compatibility and blood typing workflows, and commonly reported modifiers. The report highlights how the code is used within transfusion medicine service lines and laboratory operations. Data gaps are noted where input lacked specific reimbursement or service-line metadata.
CPT Code Overview
CPT 86850 is an antibody screen performed using each serum technique to detect unexpected red blood cell antibodies that may cause transfusion reactions or hemolytic disease. This test assesses patient serum against reagent red cells to identify clinically significant alloantibodies.
Service Type: Transfusion Medicine Procedures
Typical Site of Service: Laboratory (POS 81)
Clinical & Coding Specifications
Clinical Context
A patient presents for pre-transfusion evaluation or investigation of hemolytic anemia. A blood specimen is sent to the transfusion medicine laboratory where technologists perform an antibody screen using serum techniques to detect clinically significant alloantibodies. Results guide compatibility testing and transfusion decisions, and may be ordered during an inpatient hospital stay or as an outpatient lab order for monitoring known antibody development.
Coding Specifications
Modifier 91 - Repeat Clinical Diagnostic Laboratory Test
- Used when the same antibody screen test is performed again on the same day to confirm or verify results.
Modifier 59 - Distinct Procedural Service
- Used when the antibody screen is a separate and distinct service from other procedures performed at the same encounter.
Associated provider taxonomies:
-
291U00000X— Clinical Medical Laboratory -
207ZP0102X— Pathology - Clinical Pathology -
207Q00000X— Family Medicine Physician
Related Diagnoses
-
Z01.83— Encounter for blood typing- Relevant when antibody screen is ordered as part of blood type confirmation or pre-transfusion testing.
-
D59.0— Drug-induced autoimmune hemolytic anemia- Relevant when hemolysis is suspected after drug exposure and antibody screening is used to detect causative antibodies.
-
D59.1— Other autoimmune hemolytic anemias- Relevant when autoimmune mechanisms are suspected; antibody screening helps identify immune-mediated red cell antibodies.
-
D59.9— Acquired hemolytic anemia, unspecified- Relevant when a cause of hemolysis is not yet defined; antibody screen contributes to diagnostic evaluation.
-
Z51.81— Encounter for therapeutic drug level monitoring- Relevant when monitoring therapy that may affect hemolysis risk or antibody formation; antibody screen may be part of the monitoring protocol.
Related CPT Codes
-
86900— Blood typing, serologic- Performed to establish ABO group; often precedes or accompanies antibody screen in pre-transfusion workup.
-
86901— Blood typing, serologic- Alternate blood typing code; used in blood grouping workflows alongside antibody screening.
-
86923— Compatibility test for each unit- Performed after an antibody screen identifies antibodies; used to test donor units for compatibility with the recipient. Commonly used sequentially after
86850in transfusion preparation.
- Performed after an antibody screen identifies antibodies; used to test donor units for compatibility with the recipient. Commonly used sequentially after
National Reimbursement Benchmarks
National commercial mean rates cluster around the BUCA (average commercial) mean of $10.14 and vary relative to Medicare, which is represented as $0.00 in the input. Cigna posts the highest national commercial mean at $12.63, with Aetna and BUCA near the middle of the commercial range and UnitedHealth Group and Blue Cross Blue Shield lower.
Rate dispersion (P75 minus P25) is narrowest for Aetna and BUCA (both $6.30 and $5.00 respectively when computed from the provided percentiles), indicating tighter distributions, while Cigna shows one of the wider spreads (P75 $13.00 vs P25 $5.60). UnitedHealth Group and Blue Cross Blue Shield show moderate dispersion. The table and chart below present the full percentile and mean breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.